Manohar Angirekula, MD
Cardiovascular Disease · Odessa, TXNPI 1023007085
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 53.7% of the total. Reporting peaked in 2019 at $19,418 and has fallen 97.7% since, to $452 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $218.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$17K
- Pfizer$8K
- E.r. Squibb & Sons, L.L.C.$3K
- Edwards Lifesciences$2K
- Baylis Medical Company Inc$868
- Boston Scientific$341
- plus $797 from 14 others
What the payments were for
- Consulting fees$14,37846%
- Speaking & faculty fees$10,65034%
- Travel & lodging$1,9856%
- Food & beverage$4,07113%
- Education$2211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 67 | $16,822 |
| Pfizer | 7 | $7,941 |
| E.r. Squibb & Sons, L.L.C. | 8 | $2,888 |
| Edwards Lifesciences | 14 | $1,648 |
| Baylis Medical Company Inc | 2 | $868 |
| Boston Scientific | 9 | $341 |
| Inari Medical, Inc. | 2 | $144 |
| Medtronic(2 entities) | 7 | $136 |
| Boehringer Ingelheim | 7 | $118 |
| AstraZeneca | 5 | $94 |
| Amgen | 3 | $62 |
| Abiomed | 3 | $58 |
| Alnylam Pharmaceuticals Inc. | 1 | $36 |
| Lundbeck LLC | 2 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Stryker | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $24 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Novartis | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$10,650
- Quadra Allure MP RF CRT Pacemkr$7,155
- Allure Quadra RF CRT Pacemaker$2,835
- Confirm Rx$2,685
- EnSite Precision Cardiac Mapping System$2,228
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,332
- NRG needle$868
- Allure CRT Pacemaker$202
- AVEIR$128
- FLOWTRIEVER CATHETER, S$123
- CT THROMBECTOMY SYSTEM KIT$123
- WATCHMAN Access System$117
How this compares
$31,305 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 719 | $694,591 |
| MultaqDronedarone Hcl | 185 | $214,232 |
| EntrestoSacubitril/Valsartan | 144 | $126,137 |
| XareltoRivaroxaban | 46 | $58,945 |
| Repatha SureclickEvolocumab | 24 | $20,726 |
| Metoprolol Succinate | 1,238 | $16,435 |
| JardianceEmpagliflozin | 11 | $8,826 |
| Atorvastatin Calcium | 1,138 | $8,051 |
| Ranolazine ErRanolazine | 83 | $7,851 |
| Repatha SyringeEvolocumab | 14 | $7,773 |
| ClopidogrelClopidogrel Bisulfate | 686 | $7,145 |
| Midodrine Hcl | 63 | $5,447 |
| Amiodarone Hcl | 222 | $5,410 |
| Carvedilol | 549 | $4,758 |
| Rosuvastatin Calcium | 211 | $4,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $7,941 | $694,591719 claims |
| NovartisEntresto | $14 | $126,137144 claims |
| Boehringer IngelheimJardiance | $118 | $8,82611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Odessa
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.